Percentage of patients aged 65 years and older that receive a peripheral nerve block for analgesia following diagnosis of isolated hip fracture within the Emergency Department
Submission Method: Registry
Appropriate Follow-up Recommendations for Ovarian-Adnexal Lesions using the Ovarian-Adnexal Reporting and Data System (O-RADS)
The percentage of final reports for female patients receiving a transvaginal ultrasound (US) examination of the pelvis (including transabdominal/transvaginal exams) where a lesion is detected, in which the radiologist describes the lesion using ORADS Lexicon Descriptors, provides ORADS score, and subsequently makes the correct clinical management recommendation based on the ORADS Risk Stratification and Management System.
Repeat screening or surveillance colonoscopy recommended within one year due to inadequate bowel preparation
Percentage of patients recommended for repeat screening or surveillance colonoscopy or an alternate tier 1 or tier 2 colorectal cancer screening modality within one year or less due to inadequate bowel preparation quality
Dihydropyrimidine Dehydrogenase (DPD) Deficiency Testing Prior to Fluoropyrimidine Treatment
Percentage of patients receiving fluoropyrimidine treatment who were tested for dihydropyrimidine dehydrogenase (DPD) deficiency prior to the initial initiation of treatment
Oncology: Advance Care Planning in Metastatic Cancer Patients
Percentage of patients with metastatic (stage 4) cancer who have a documented Advance Care Planning discussion in the first 6 months after metastatic diagnosis to inform treatment decisions and end-of-life care.
Oncology: Patient-Reported Pain Improvement
Percentage of cancer patients currently receiving chemotherapy or radiation therapy who report significant pain improvement (high to moderate, moderate to low, or high to low) within 30 days.
Oncology: Supportive Care Drug Utilization in Last 14 Days of Life
Percentage of patients receiving supportive care drugs (including colony stimulating factors, bone health, supplemental iron medications, and neurokinin 1 (NK1) receptor antagonist antiemetics) during the 14 days prior to and including the date of death.
Oncology: Hepatitis B Serology Testing and Prophylactic Treatment Prior to Receiving Anti-CD20 Targeting Drugs
Percentage of patients tested for Hepatitis B prior to receiving anti-CD20 targeting treatment, including rituximab, ofatumumab, and obinutuzumab; patients testing positive for Hepatitis B receive prophylactic treatment.
Oncology: Mutation Testing for Stage IV Lung Cancer Completed Prior to the Start of Targeted Therapy
Proportion of stage IV nsNSCLC patients tested for actionable biomarkers and received targeted therapy or chemotherapy based on biomarker results
Patients Suffering From an Upper Extremity Injury who Improve Pain
Percentage of patients 18 years or older suffering from an upper extremity injury who achieve the Minimal Clinically Important Difference (MCID) in the Numeric Pain Rating Scale, or like mapped measure during the performance year.
Additionally, a risk-adjusted MCID proportional difference determined by calculating the difference between the risk model predicted and observed MCID proportion will be reported for each PT/OT/MSK Provider/Group. The risk adjustment will be calculated using a logistic regression model using: baseline function score, baseline pain score, age, sex, payer, surgical status, and symptom duration (time from surgery or symptom onset to baseline physical therapy visit) as well as instrument tool used. These measures will serve as a PT/OT/MSK Provider performance measure at the eligible PT/OT/MSK Provider or group level.
This measure will include one rate:
1) The overall performance rate of non-surgical and surgical patients who achieve the MCID in the Numeric Pain Rating Scale like mapped measure.